Skye Bioscience annual operating income
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Skye Bioscience Operating Income Growth & History (SKYE)
Skye Bioscience's operating income was −$58.2M for fiscal 2025.
View full Skye Bioscience company overviewSkye Bioscience annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$58.2M | −$28.0M | — |
| 2024 | 2024-12-31 | −$30.2M | $4.5M | — |
| 2023 | 2023-12-31 | −$34.7M | −$16.4M | — |
| 2022 | 2022-12-31 | −$18.3M | −$10.5M | — |
| 2021 | 2021-12-31 | −$7.8M | −$1.6M | — |
| 2020 | 2020-12-31 | −$6.3M | $343,565 | — |
| 2019 | 2019-12-31 | −$6.6M | −$1.9M | — |
| 2018 | 2018-12-31 | −$4.7M | −$833,294 | — |
| 2017 | 2017-12-31 | −$3.9M | $611,351 | — |
| 2016 | 2016-12-31 | −$4.5M | −$153,470 | — |
| 2015 | 2015-12-31 | −$4.3M | −$1.6M | — |
| 2014 | 2014-12-31 | −$2.7M | −$2.6M | — |
| 2013 · Dec 31 | 2013-12-31 | −$120,403 | — | — |
| 2013 · Oct 31 | 2013-10-31 | −$7,242 | −$11,359 | — |
| 2012 | 2012-10-31 | $4,117 | — | — |
Skye Bioscience quarterly operating income
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q3.14
Q4.13
Q1.14
Q1.14
Q1.14
Q2.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q4.19
Q1.20
Q2.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$11.1M | $7.2M | — |
| Q1 2026 | 2026-03-31 | −$12.7M | −$914,804 | — |
| Q4 2025 | 2025-12-31 | −$14.9M | −$4.2M | — |
| Q3 2025 | 2025-09-30 | −$13.3M | −$8.3M | — |
| Q2 2025 | 2025-06-30 | −$18.2M | −$9.8M | — |
| Q1 2025 | 2025-03-31 | −$11.8M | −$5.6M | — |
| Q4 2024 | 2024-12-31 | −$10.7M | −$6.6M | — |
| Q3 2024 | 2024-09-30 | −$5.0M | $19.7M | — |
| Q2 2024 | 2024-06-30 | −$8.4M | −$5.6M | — |
| Q1 2024 | 2024-03-31 | −$6.2M | −$3.1M | — |
| Q4 2023 | 2023-12-31 | −$4.1M | $5.2M | — |
| Q3 2023 | 2023-09-30 | −$24.7M | −$21.8M | — |
| Q2 2023 | 2023-06-30 | −$2.8M | $375,363 | — |
| Q1 2023 | 2023-03-31 | −$3.1M | −$212,137 | — |
| Q4 2022 | 2022-12-31 | −$9.3M | −$6.8M | — |
| Q3 2022 | 2022-09-30 | −$2.9M | −$1.1M | — |
| Q2 2022 | 2022-06-30 | −$3.2M | −$1.4M | — |
| Q1 2022 | 2022-03-31 | −$2.9M | −$1.2M | — |
| Q4 2021 | 2021-12-31 | −$2.5M | −$1.1M | — |
| Q3 2021 | 2021-09-30 | −$1.8M | −$280,889 | — |
| Q2 2021 | 2021-06-30 | −$1.8M | −$609,016 | — |
| Q1 2021 | 2021-03-31 | −$1.7M | $473,946 | — |
| Q4 2020 | 2020-12-31 | −$1.3M | $524,583 | — |
| Q2 2020 | 2020-09-30 | −$1.5M | −$35,106 | — |
| Q1 2020 | 2020-06-30 | −$1.2M | $550,229 | — |
| Q4 2019 | 2020-03-31 | −$2.2M | −$696,141 | — |
| Q4 2019 | 2019-12-31 | −$1.8M | −$528,158 | — |
| Q3 2019 | 2019-09-30 | −$1.5M | −$457,494 | — |
| Q2 2019 | 2019-06-30 | −$1.8M | −$690,697 | — |
| Q1 2019 | 2019-03-31 | −$1.5M | −$263,706 | — |
| Q4 2018 | 2018-12-31 | −$1.3M | −$328,833 | — |
| Q3 2018 | 2018-09-30 | −$1.0M | −$283,990 | — |
| Q2 2018 | 2018-06-30 | −$1.1M | −$349,263 | — |
| Q1 2018 | 2018-03-31 | −$1.3M | $128,792 | — |
| Q4 2017 | 2017-12-31 | −$986,519 | −$74,461 | — |
| Q3 2017 | 2017-09-30 | −$761,630 | $94,518 | — |
| Q2 2017 | 2017-06-30 | −$730,927 | $751,108 | — |
| Q1 2017 | 2017-03-31 | −$1.4M | −$159,814 | — |
| Q4 2016 | 2016-12-31 | −$912,058 | $242,391 | — |
| Q3 2016 | 2016-09-30 | −$856,148 | $40,144 | — |
| Q2 2016 | 2016-06-30 | −$1.5M | −$125,491 | — |
| Q1 2016 | 2016-03-31 | −$1.2M | −$310,514 | — |
| Q4 2015 | 2015-12-31 | −$1.2M | — | — |
| Q3 2015 | 2015-09-30 | −$896,292 | −$38,679 | — |
| Q2 2015 | 2015-06-30 | −$1.4M | −$1.2M | — |
| Q1 2015 | 2015-03-31 | −$909,825 | −$879,724 | — |
| Q3 2014 · Sep 30 | 2014-09-30 | −$857,613 | −$827,512 | — |
| Q2 2014 · Jul 31 | 2014-07-31 | $4,052 | $3,308 | +444.62% |
| Q2 2014 · Jun 30 | 2014-06-30 | −$142,920 | — | — |
| Q1 2014 · Apr 30 | 2014-04-30 | −$13,431 | −$17,043 | — |
| Q1 2014 · Mar 31 | 2014-03-31 | −$30,101 | — | — |
| Q1 2014 · Jan 31 | 2014-01-31 | −$1,230 | $4,964 | — |
| Q4 2013 | 2013-12-31 | −$94,658 | — | — |
| Q3 2014 · Sep 30 | 2013-09-30 | −$30,101 | — | — |
| Q3 2013 | 2013-07-31 | $744 | $837 | — |
| Q2 2013 | 2013-04-30 | $3,612 | $4,162 | — |
| Q1 2013 | 2013-01-31 | −$6,194 | — | — |
| Q3 2012 | 2012-07-31 | −$93 | — | — |
| Q2 2012 | 2012-04-30 | −$550 | — | — |
Skye Bioscience operating income trends
Over the last five fiscal years, Skye Bioscience's operating income decreased from −$6.3M to −$58.2M, a change of −$51.9M. The latest reported quarter, Q2 2026, shows −$11.1M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Skye Bioscience source filings ↗